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Abstract
Breast cancer is the most common cancer in women worldwide. Doxorubicin-based chemo-
therapy is used to treat breast cancer patients; however, neutropenia is a common hemato-
logic side effect and can be life-threatening. The ABCB1 and SLC22A16 genes encode
proteins that are essential for doxorubicin transport. In this study, we explored the effect of 2
common polymorphisms in ABCB1 (rs10276036 C/T) and SLC22A16 (rs12210538 A/G) on
the development of grade 3/4 febrile neutropenia in Iranian breast cancer patients. Our
results showed no significant association between these polymorphisms and grade 3/4
febrile neutropenia; however, allele C of ABCB1 (rs10276036 C/T) (p = 0.315, OR = 1.500,
95% CI = 0.679–3.312) and allele A of SLC22A16 (rs12210538 A/G) (p = 0.110, OR =
2.984, 95% CI = 0.743–11.988) tended to have a greater association with grade 3/4 febrile
neutropenia, whereas allele T of ABCB1 (rs10276036) (p = 0.130, OR = 0.515, 95% CI =
0.217–1.223) and allele G of SLC22A16 (rs12210538) (p = 0.548, OR = 0.786, 95% CI =
0.358–1.726) tended to protect against this condition. In addition to breast cancer, a statisti-
cally significant association was also observed between the development of grade 3/4
febrile neutropenia and other clinical manifestations such as stage IIIC cancer (p = 0.037)
and other diseases (p = 0.026). Our results indicate that evaluation of the risk of grade 3/4
neutropenia development and consideration of molecular and clinical findings may be of
value when screening for high-risk breast cancer patients.
Introduction
Breast cancer is the most incident cancer type among women. Doxorubicin (DOX)-based
treatments are appropriate for many adult and pediatric solid tumors (including breast can-
cer), leukemias and lymphomas [1]. However, optimized administration of DOX is hampered
owing to some toxicities, such as hematopoietic suppression, nausea, vomiting, and cardiotoxi-
city [2].
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DOX is a secondary metabolite produced by Streptomyces peucetius var. caesius and belongs
to the family of anthracyclines [3]. DOX functions through dual mechanisms i) intercalation
into DNA and disruption of the DNA repair mechanism that is mediated by topoisomerase II,
and ii) releasing of free radicals resulting in the damaging of cell membranes, DNA, and pro-
teins [4]. DOX is oxidized to a semiquinone, an unstable metabolite, which is reconverted to
DOX through a pathway that releases reactive oxygen species; this can cause lipid peroxida-
tion, membrane damage, DNA damage, oxidative stress, and cell death via induction of apo-
ptotic pathways (Fig 1) [5].
Administration of DOX causes myelosuppression and leads to anemia, thrombocytopenia,
and leukopenia. Neutropenia causes immune system suppression, exposing the patient to
severe life-threating infections; it is the most serious hematologic toxicity associated with can-
cer chemotherapy, and its degree and duration determine the risk of infection. Prophylaxis
with granulocyte-colony stimulating factor reduces the intensity and duration of chemother-
apy-induced neutropenia and attenuates febrile neutropenia risk, and therefore plays a signifi-
cant role in supporting myelosuppressive chemotherapy [6].
A number of factors have been shown to impact the response to DOX-based chemotherapy,
including tumor stage, grade, the number of involved lymph nodes, and expression levels of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor
receptor 2 (Her2) [7]. However, inter-patient variability has created a major obstacle for the
clinical use of anticancer drugs [8]. Studies showed that these variations may be caused by dif-
ferences in metabolizing enzymes and transporters associated with DOX. DOX is transported
by the protein encoded by the ABCB1 gene [9–11] as well as the solute transporter encoded by
Fig 1. Transport and mechanism of action of doxorubicin.
doi:10.1371/journal.pone.0168519.g001
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SLC22A16 [12, 13]. ABCB1 (MDR1) belongs to the adenosine triphosphate binding cassette
family genes [14], while SLC22A16 is a member of the organic cation transporter family [15].
Each of these transporter genes has been shown to carry genetic variations in the form of single
nucleotide polymorphisms [16–18].
Since neutropenia is one of the adverse effects of DOX administration, the aim of this study
was to investigate the possibility that ABCB1 (rs10276036C/T) and SLC22A16 (rs12210538A/
G) gene polymorphisms play a role in the development of neutropenia in Iranian breast cancer
patients treated with DOX-based chemotherapy.
Methodology
Patient information and neutropenia grading
In this case-controlled study, 100 women with breast cancer who were administered DOX-based
neoadjuvant chemotherapy were selected as our study cohort. All patients were referred to the
Department of Radiation Oncology of the 7-Tir Hospital in Tehran, and the presence of neutro-
penia was determined and graded based on their blood test report and according to the Common
Terminology Criteria for Adverse Events Version 4.0. Two distinct groups were established.
The “case” group of 50 patients included those who were treated with DOX-based chemo-
therapy and had a neutrophil count1.0 × 109/L and encompassed patients with grade 3/4
febrile neutropenia, and the “control” group (50 patients) included those who were treated
with DOX-based chemotherapy and had a neutrophil count>1.0 × 109/L (patients with
neutropenia grade 2).
Blood collection and DNA extraction
After approval of the study by the ethics committee of the National Institute of Genetic Engi-
neering and Biotechnology (approval code IR.NIGEB.EC.1395.5.30.A) and obtaining written
informed consent from all patients, 2–3 mL of whole blood was collected into tubes containing
EDTA from each; samples were stored at 4˚C. Genomic DNA was extracted by using the GPP
Solution Kit (Gene Pajoohan Pouya Co., Iran). Extracted DNA samples were separated on 1%
agarose gels to check their quality, and were then quantified by using the UV-Vis spectropho-
tometer (NanoDrop 2000, Thermo Scientific, USA).
Primer design, genotyping, and DNA sequencing
The amplification refractory mutation system-polymerase chain reaction (ARMS-PCR)
method was used for genotyping the ABCB1 (rs10276036C/T) and SLC22A16 (rs12210538A/
G) gene polymorphisms; the primers were designed using the WASP software (Genome Insti-
tute-BIOTEC, Thailand) and are shown in Table 1.
Table 1. Amplification refractory mutation system (ARMS) and standard-PCR primers for genotyping and sequencing of ABCB1 (rs10276036 C/T)
and SLC22A16 (rs12210538 A/G) gene polymorphisms.
Method Polymorphism Sequence (5’! 3’) Size (bp)
ARMS-PCR ABCB1 (rs10276036) WF: CCATCAGGCTACTGAGATAGTGTCMF: CCATCAGGCTACTGAGATAGTGTTCR:
GAGCCCAGGAGGTAGAGGTT
262
SLC22A16
(rs12210538)
WR: CTTCGTGTGCATCGCCTTMR: CTTCGTGTGCATCGCCTCCF: TCTGCCCAAATCATACTCTGAA 215
Standard-
PCR
ABCB1 (rs10276036) F: TTGTGGAGAGCTGGATAAAGTGR:AGCCCAGGAGGTAGAGGTTATG 482
SLC22A16
(rs12210538)
F: CCTGAACTCAAGCCATCCTCR:CTGCCTCGCAGCAATTCTTAG 581
doi:10.1371/journal.pone.0168519.t001
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Primers were synthesized by Macrogen, Korea. The PCR program was as follows: 1 cycle:
first denaturation at 95˚C for 5 min; 35 cycles: denaturation at 95˚C for 1 min, annealing at
59˚C for 50 s, and extension at 72˚C for 50 s; and 1 cycle: final extension at 72˚C for 5 min.
PCR reactions were prepared according to the standard protocols [19].
The PCR products were then separated by electrophoresis on 1.5% agarose gels at 80–100 V
for 40–50 min. The gel was stained with ethidium bromide and visualized under ultraviolet
light using a full high-definition camera (Canon SX710HS, Japan). To assess the accuracy of
the ARMS-PCR primers, 3 PCR products representing a wild homozygote, heterozygote, and
mutant homozygote of each of the studied polymorphisms were sequenced; results were ana-
lyzed by using the NCBI Blast software (Fig 2A–2H).
Data analysis
Statistical analysis was performed by using the IBM SPSS Statistics software ver. 23. Statistical
analysis was performed on demographic, molecular, and clinical findings; the significance
level was set at p<0.05.
Fig 2. Fig 2A. Agarose gel image of the amplification refractory mutation system-PCR products of the ABCB1 gene polymorphism (rs10276036 C/
T). 1: 50 bp DNA ladder, 2 & 3: heterozygote allele C/T, 4 & 5: homozygote allele C, 6 & 7: homozygote allele T, 8 & 9: negative control for alleles C and T
respectively, Fig 2B. Electropherogram of the ABCB1 gene polymorphism (rs10276036 C/T) homozygote allele C, Fig 2C. Electropherogram of the
ABCB1 gene polymorphism (rs10276036 C/T) homozygote allele T, Fig 2D. Electropherogram of the ABCB1 gene polymorphism (rs10276036 C/T)
heterozygote allele C/T, Fig 2E. Agarose gel image of the amplification refractory mutation system-PCR products of the SLC22A16 gene
polymorphism (rs12210538 A/G). 1: 50 bp DNA ladder, 2 & 3: heterozygote allele A/G, 4 & 5: homozygote allele A, 6 & 7: homozygote allele G, 8 & 9:
negative control for alleles A and G respectively, Fig 2F. Electropherogram of the SLC22A16 gene polymorphism (rs12210538 A/G) homozygote allele
A, Fig 2G. Electropherogram of the SLC22A16 gene polymorphism (rs12210538 A/G) homozygote allele G, Fig 2H. Electropherogram of the
SLC22A16 gene polymorphism (rs12210538 A/G) heterozygote allele A/G.
doi:10.1371/journal.pone.0168519.g002
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Results
Distribution of neutropenia and patient demographics
In our cohort, 18% of the patients had no neutropenia; 19% had grade I, 13% had grade II,
42% had grade III, and 8% had grade IV neutropenia. Patient demographics are shown in
Table 2.
Distribution of ethnicity and other malignancies
Fars (54%) and Turk (24%) ethnicities were the most prevalent in our cohort; based on the
Pearson chi-square test, there was no significant association between ethnicity and the inci-
dence of grade 3/4 febrile neutropenia (p = 0.191).
Most patients (70%) had no other malignancies besides breast cancer; however, 4 patients
in the case group had blood hypertension, 4 had heart disease, and 4 had liver problems. On
the other hand, 1 patient in the control group had arthritis and another had Parkinson’s dis-
ease. Based on the Pearson chi-square test, there was a significant association between the exis-
tence of diseases other than breast cancer and grade 3/4 febrile neutropenia (p = 0.026).
Genotyping
The frequencies of alleles C and T in the ABCB1 gene polymorphism (rs10276036C/T) in our
patients were 42.5% and 57.5%, respectively, whereas the frequencies of CC, CT, and TT geno-
types were 28%, 29%, and 43%, respectively. The distributions were different in both patient
groups; details are shown in Table 3.
The frequencies of alleles A and G in the SLC22A16 gene polymorphism (rs12210538A/G)
in the patients were 68% and 32%, respectively, whereas those of genotype AA, AG, and GG
were 47%, 42%, and 11%, respectively. The distribution also differed between the 2 groups, as
shown in Table 4.
Table 2. Demographic characteristics of the cohorts.
Character Minimum Maximum Mean St. Deviation p
Age (y) 24 82 48.5 9.628 0.77
BMI (kg/m2) 18.70 51.92 28.42 5.36 0.593
W.B.C Count (M/ul) 0.5 10.4 4.176 1.5397 -
doi:10.1371/journal.pone.0168519.t002
Table 3. Allele and genotype analysis of the ABCB1 gene polymorphism (rs10276036 C/T).
Allele/Genotype Freq. % Dis. OR 95% CI RR 95% CI p
C 42.5 Case: 30 1.500 0.679–3.312 1.227 0.818–1.842 0.315
Control: 25
T 57.5 Case: 31 0.515 0.217–1.223 0.733 0.500–1.075 0.130
Control: 38
CC 28 Case: 16 1.490 0.618–3.592 1.210 0.809–1.811 0.373
Control: 12
CT 29 Case: 15 1.102 0.464–2.615 1.049 0.687–1.602 0.826
Control: 14
TT 43 Case: 19 0.664 0.299–1.472 0.812 0.538–1.226 0.313
Control: 24
doi:10.1371/journal.pone.0168519.t003
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Clinical findings
In terms of cancer histology, both groups had an equal distribution of ductal carcinoma (48%
each) and of lobular carcinoma (2% each).
As for cancer stages, stage IA was the least prevalent (11%), while stage IIA was the most
(28%). Based on the Pearson chi-square test, there was a significant association between stage
IIA (p = 0.026) and stage IIIC (p = 0.037) with grade2 and grade 3/4 febrile neutropenia,
respectively.
In terms of tumor grade, grades I and II were the least and most frequent at 9% and 72%,
respectively.
Furthermore, the frequencies of ER, PR, and Her2 positivity were above 50% in our
patients.
As for chemotherapy, ATC (adriamycin, taxotere, and cyclophosphamide) was the most
frequently administered regimen (64%), whereas CAF (cyclophosphamide, adriamycin, and
5-fluorouracil) was the least commonly administered (17%). The Pearson chi-square test
showed no significant association between the type of chemotherapy regimen and grade 3/4
febrile neutropenia (p = 0.917). Details are summarized in Table 5.
Discussion
Febrile neutropenia frequently occurs during DOX-based chemotherapy administration.
Patients who experience febrile neutropenia are more likely to show poorer treatment out-
comes during chemotherapy [20]; such patients often experience drug dose-related complica-
tions that lead to toxic side effects. Furthermore, these patients have longer hospitalization
periods and are administered more antibiotics. It was previously reported that the incidence of
febrile neutropenia in Korean breast cancer patients undergoing DOX-based chemotherapy
was 29.5% [21].
In recent years, the survival rates of breast cancer patients have been improved. To further
improve outcomes, the development of specific therapeutic protocols based on individuals’
genetic profiles is essential. Moreover, genetic polymorphisms were shown to affect neutro-
phil counts in patients who are administered DOX-based chemotherapy [22]; in these stud-
ies, the emergence of chemotherapy-induced severe toxicities was more frequent in Asian
patients than in Western patients, suggesting that the former are more susceptible to febrile
neutropenia.
In this study, we explored the role of ABCB1 (rs10276036C/T) and SLC22A16 (rs12210538
A/G) gene polymorphisms in the development of grade 3/4 febrile neutropenia in Iranian
Table 4. Allele and genotype analysis of the SLC22A16 gene polymorphism (rs12210538 A/G).
Allele/Genotype Freq. % Dis. OR 95% CI RR 95% CI p
A 68 Case: 47 2.984 0.743–11.988 1.936 0.723–5.184 0.110
Control: 42
G 32 Case: 25 0.786 0.358–1.726 0.887 0.600–1.311 0.548
Control: 28
AA 47 Case: 25 1.273 0.579–2.795 1.128 0.763–1.668 0.548
Control: 22
AG 42 Case: 22 1.179 0.532–2.610 1.085 0.733–1.607 0.685
Control: 20
GG 11 Case: 3 0.335 0.083–1.346 0.516 0.193–1.383 0.110
Control: 8
doi:10.1371/journal.pone.0168519.t004
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breast cancer patients who were administered DOX-based chemotherapy. The ABCB1
(rs10276036C/T) gene polymorphism is located in the intronic region, while the SLC22A16
(rs12210538A/G) gene polymorphism is a non-synonymous polymorphism that substitutes
methionine with threonine at position 409. Expression of the SLC22A16 gene in cancer cells
was associated with increased sensitivity to the cytotoxic effects of DOX [12].
Previous studies revealed that drug transporter genes such as ABCB1 [23] and SLC22A16
likely affect the systemic pharmacodynamics of DOX [24]. Furthermore, Bray and colleagues
studied the association of polymorphic variants of the ABCB1 and SLC22A16 genes with drug
toxicity in breast cancer patients treated with DOX, and found that polymorphisms are associ-
ated with the development of toxicities [25].
Many pharmacogenetic studies have also investigated the effect of ABCB1 gene polymor-
phisms in the emergence of chemotherapy-induced side effects. In their study, Sissung and
colleagues described an association between ABCB1 gene polymorphisms and toxicities such
as nephropathy, neutropenia, and survival in 23 patients who were undergoing chemotherapy
[26].
In another study, it was observed that ABCB1 and SLC22A16 gene polymorphisms were
associated with drug-induced side effects such as leukopenia, although they had no effect on
survival [13]. Furthermore, it has been demonstrated that the ABCB1 variant 13435 C/T is
associated with greater mRNA instability, which can lead to more prevalent grade 3/4 febrile
neutropenia [23].
Table 5. Clinical characteristics of the patients.
Character Freq. % Dis. OR 95% CI RR 95% CI p
Ductal Carcinoma 96 Case: 48 1.000 0.135–7.392 1.000 0.368–2.719 1.000
Control: 48
Lobular Carcinoma 4 Case: 2 1.000 0.135–7.392 1.000 0.368–2.719 1.000
Control: 2
Cancer Stage IA 11 Case: 6 1.227 0.349–4.316 1.103 0.618–1.968 0.749
Control: 5
Cancer Stage IIA 28 Case: 9 0.358 0.143–0.899 0.564 0.318–1.003 0.026
Control: 19
Cancer Stage IIB 23 Case: 10 0.712 0.279–1.818 0.837 0.501–1.398 0.476
Control: 13
Cancer Stage IIIA 25 Case: 15 1.714 0.683–4.301 1.286 0.861–1.920 0.248
Control: 10
Cancer Stage IIIC 13 Case: 10 3.917 1.008–15.220 1.673 1.150–2.434 0.037
Control: 3
Tumor Grade I 9 Case: 5 1.278 0.322–5.066 1.123 0.604–2.089 0.727
Control: 4
Tumor Grade II 72 Case: 36 1.000 0.418–2.394 1.000 0.646–1.547 1.000
Control: 36
Tumor Grade III 19 Case: 9 0.878 0.323–2.388 0.936 0.556–1.575 0.799
Control: 10
ER+ 74 Case: 36 0.812 0.332–1.989 0.903 0.590–1.383 0.648
Control: 38
PR+ 70 Case: 33 0.682 0.288–1.614 0.832 0.558–1.240 0.383
Control: 37
Her2+ 52 Case: 25 0.852 0.388–1.868 0.923 0.624–1.366 0.689
Control: 27
doi:10.1371/journal.pone.0168519.t005
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Even though our study revealed no significant association between ABCB1 (rs10276036C/
T) and SLC22A16 (rs12210538A/G) gene polymorphisms and grade 3/4 febrile neutropenia,
ABCB1 (rs10276036C/T) allele C polymorphisms (genotypes CC and CT) and SLC22A16
(rs12210538A/G) allele A polymorphisms (genotypes AA and AG) tended to be associated
with more frequent grade 3/4 febrile neutropenia. On the other hand, the ABCB1 (rs10276036
C/T) allele T polymorphism (genotype TT) and the SLC22A16 (rs12210538A/G) allele G
polymorphism (genotype GG) appeared to have a protective role against grade 3/4 febrile
neutropenia.
Conclusions
Our results show that carriers of at least one allele C of ABCB1 (rs10276036C/T) polymor-
phism and at least one allele A of SLC22A16 (rs12210538A/G) polymorphism tend to be more
susceptible to grade 3/4 febrile neutropenia. Therefore, a combination of additional molecular
and clinical tests ought to be useful for evaluating the risk of grade 3/4 febrile neutropenia.
This study included limitations such as the fact that not all genes related to DOX metabo-
lism and transport were investigated, and that the results are based on examining patients who
underwent DOX-based combination chemotherapy and not DOX alone. Furthermore, the
study included a small cohort size, and all patients were from a single clinical center, where
administration of prophylactic granulocyte-colony stimulating factor and of overall drug doses
was at the physicians’ discretion. To validate the results of this study, further investigations
with larger cohort sizes in various populations are required to further explore the effect of
these polymorphisms in the development of grade 3/4 febrile neutropenia.
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